{{Infobox company | name = BB Biotech AG | logo = BB Biotech Logo 2022.svg | logo_size = 235px | type = Aktiengesellschaft | traded_as = {{SWX|BION}}<ref>{{cite web |title=BB Biotech AG |work=Reuters |url=https://www.reuters.com/companies/BION.S/listings |access-date=2021-10-20 |language=en}}</ref>{{br}}{{FWB|BBZA}}<ref>{{cite web |title=BB Biotech AG Equity |url=https://www.boerse-frankfurt.de/equity/bb-biotech-ag |work=Börse Frankfurt |access-date=2021-10-20}}</ref> | foundation = {{Start date|1993|11|9|df=yes}}<ref name="HR_SH">{{cite web |last1=AG |first1=DV Bern |title=BB Biotech AG |url=https://sh.chregister.ch/cr-portal/auszug/auszug.xhtml?uid=CHE-102.169.627 |work=Official Companies Register of the Canton of Schaffhausen |access-date=2021-10-20 |language=de}}</ref> | founder = | location = Schaffhausen, Switzerland<ref>{{cite web |title=BB Biotech AG |url=https://www.zefix.ch/de/search/entity/list/firm/326726 |work=Zentraler Firmenindex |access-date=2021-10-20 |language=de}}</ref> | locations = | key_people = Thomas von Planta {{br}}<small>(Chairman)</small><ref name="board">{{cite web |title=Board of Directors |url=https://www.bbbiotech.ch/en/bb-biotech/about-us/board-of-directors |work=BB Biotech |access-date=2024-07-01}}</ref> | industry = Investment company | products = Investment in biotechnology companies | net_income = {{Increase}} CHF 578 million{{br}}<small>(2025)</small><ref name="AR 2025">{{cite web |url=https://www.bbbiotech.ch/_Resources/Persistent/7/4/6/c/746cb818af6a39ab5739cd1965eb90e4e93dae2a/BB%20Biotech%20AG%20GB%202025_en.pdf |title=Annual Report 2025 |work=BB Biotech |date=2026 |access-date=2026-03-31}}</ref> | assets = {{increase}} CHF 2,786 billion{{br}}<small>(2025)</small><ref name="AR 2025" /> | services = Investment company | divisions = | subsid = | homepage = [http://www.bbbiotech.ch www.bbbiotech.ch] }}
'''BB Biotech AG''' is a Swiss investment company in the field of biotechnology. The company invests mainly in the United States and Western Europe<ref name="BB">{{cite web |title=BB Biotech AG |url=https://www.bloomberg.com/quote/BB:IM |work=Bloomberg |access-date=2022-01-08}}</ref> and is managed by Bellevue Asset Management, a division of Bellevue Group, which is listed on the Swiss Stock Exchange.<ref name="quoteddata">{{cite web |date=2021-02-11 |title=BB Biotech AG, A leading biotech investor |url=https://quoteddata.com/wp-content/uploads/2021/02/210211-BION-Initiation-IN.pdf |access-date=2024-07-01 |work=QuotedData}}</ref>
It is one of the largest investment companies in the biotech sector.<ref>{{cite web |url=https://www.wiwo.de/themen/bb-biotech |title=Themenschwerpunkt: BB Biotech |trans-title=Main Theme: BB Biotech |work=Wirtschaftswoche |access-date=2024-06-29 |language=de}}</ref><ref name=":0">{{cite news |date=2021-02-12 |title=Aktien-Rückblick: BB Biotech Boom, Boom, Biotech |work=Wirtschaftswoche |language=de}}</ref>
== History == BB Biotech was founded as an ''Aktiengesellschaft'' on November 9, 1993 in Schaffhausen, Switzerland.<ref name="HR_SH"/><ref name="BB_Finportal">{{cite web |url=https://www.boerse.de/aktien/BB-Biotech-Aktie/CH0038389992 |title=BB Biotech Aktie |work=Boerse.de |access-date=2024-06-29}}</ref> The company's shares have been traded on the SIX Swiss Exchange since December 27, 1993,<ref name="BB_Finportal"/><ref name="boersennews">{{cite web |url=https://www.boersennews.de/markt/aktien/detail/ch0038389992/ |title=BB Biotech |work=Börsennews.de |access-date=2024-06-29}}</ref> and since December 10, 1997 on the German Deutsche Börse in Frankfurt.<ref name="boersennews"/><ref name="aktienprognose">{{cite web |url=http://www.aktien-prognose.com/aktienkurs/bb+biotech/ |title=BB Biotech |work=Aktien Prognose |access-date=2024-07-01}}</ref> BB Biotech was listed on the TecDAX from 2003 to June 2012,<ref name="aktienprognose"/> and returned to it again between September 2012 and June 2015.<ref name="BB_Biotech-Aktie"/> The shares were listed on the Italian Nuovo Mercato from October 19, 2000 to September 4, 2023,<ref name="delisting">{{Cite web |date=2023-08-21 |title=Delisting from Borsa Italiana |url=https://www.bbbiotech.ch/ch-en/private/investors/corporate-news/delisting-from-borsa-italiana |access-date=2023-08-31 |work=BB Biotech}}</ref><ref>{{cite news |title=BB Biotech geht an den Nuovo Mercato. |work=Handelsblatt |date=2000-10-11 |language=de}}</ref> since September 2005 in the Star segment (TechStar).<ref name="BB_Biotech-Aktie">{{cite web |url=https://www.investor-verlag.de/aktien-und-aktienhandel/tecdax/bb-biotech-aktie/ |title=BB Biotech AG |work=Investor Verlag |access-date=2024-06-30}}</ref>
==Investment activities== === Investment area === As a closed-end fund, with its principal activity of specialised investments in companies operating in the biotech sector,<ref name ="BB" /><ref name="cnbc1">{{cite web |title=BB Biotech AG, 0JYO-GB: London Stock Exchange |url=https://www.cnbc.com/quotes/0JYO-GB?tab=profile |work=CNBC |access-date=2022-06-02 |language=en}}</ref> BB Biotech is the oldest established and largest entity of its kind.<ref name="quoteddata"/><ref>{{cite web |title=BB Biotech AG – BIOEE |url=https://tools.morningstar.co.uk/uk/stockreport/default.aspx?SecurityToken=0P00012CR2%5D3%5D0%5DE0WWE%24%24ALL |work=Morningstar |access-date=2022-06-02}}</ref> Primary focus lies on small-to-mid-cap biotech companies headquartered in Western Europe<ref>{{cite web |title=DGAP-News: BB Biotech AG: Disruptive technologies are changing an entire industry. |url=https://www.finanzen.ch/nachrichten/aktien/dgap-news-bb-biotech-ag-disruptive-technologies-are-changing-an-entire-industry-1031483645 |work=Finanzen.ch |access-date=2022-06-02 |date=2022-05-24}}</ref> and especially the United States market.<ref>{{cite web |title=BB Biotech AG, BION:SWX profile |url=https://markets.ft.com/data/investment-trust/tearsheet/profile?s=BION:SWX |work=Financial Times Markets |access-date=2024-07-01}}</ref><ref name="investments">{{cite web |url=https://www.bbbiotech.ch/ch-en/private/portfolio-strategy/performance-portfolio/our-investments |title=Our investments |work=BB Biotech |access-date=2024-07-01}}</ref>
The biotechnology companies in which BB Biotech invests are active, for example, in the fields of oncology, the development of drugs for the treatment of neurological disorders, metabolic diseases, cardiovascular diseases infectious diseases and autoimmune diseases.<ref name=":0" /><ref name="cnbc1"/><ref>{{cite news |date=2022-11-04 |title=Solides Portfolio, aktionärsfreundliche Politik |work=Wirtschaftswoche |language=de}}</ref> BB Biotech further concentrates on firms developing therapeutic products<ref name="BB" /> involving cell, gene and particularly RNA-based technologies.<ref name="quoteddata"/>
In contrast to other biotech specialists or hedge funds, Biotech is a long-only investor and does not need to rely on financial instruments to reduce individual stock or market risk.<ref name="quoteddata"/> It targets biotechnology firms which either have previously established products in the marketplace<ref>{{cite web |title=BB Biotech AG Bearer Shares (BBAGF) |url=https://www.nasdaq.com/de/market-activity/stocks/bbagf |work=Nasdaq, Inc. |access-date=2022-06-02}}</ref> or promising drug candidates in advanced development stages.<ref name="edisonGJ">{{cite web |title=BB Biotech SW: BION |url=https://www.edisongroup.com/company/bb-biotech/ |work=Edison Investment Research Limited |access-date=2022-06-02}}</ref>
=== Companies and core investments === While benchmarked against the Nasdaq Biotech index (in CHF),<ref>{{cite web |last1=Kadhim Shubber |title=US biotech tumbles into bear market |url=https://www.ft.com/content/6ab18706-4a70-11e5-9b5d-89a026fda5c9 |work=Financial Times |access-date=2022-06-02 |date=2015-08-24}}</ref><ref>{{cite web |author=Richard Evans |title=Questor: biotech has been shunned this year despite the vaccines triumph – so buy these trusts |url=https://www.telegraph.co.uk/investing/shares/questor-biotech-has-shunned-year-despite-vaccines-triumph/ |work=The Telegraph |access-date=2022-06-02 |date=2021-12-09}}</ref> the company uses a bottom-up approach<ref name="edisonGJ"/> based on the fundamental analysis.<ref name="quoteddata"/> Its portfolio comprises around 35 companies.<ref name="cnbc1"/>
The portfolio usually includes five to eight core holdings, which account for around 70% of the total value, as well as around two dozen smaller holdings. In addition, up to 10% may be held in non-listed companies (Private equity).<ref name="HR_SH" />
The core investments in the BB Biotech portfolio as of December 31, 2024 included Argenx (13.7%), Ionis Pharmaceuticals (10.0%), Neurocrine Biosciences (9.4%), Intra-Cellular Therapies (7.6%), Revolution Medicines (7.2%), Vertex (7.2%), Alnylam Pharmaceuticals (6.7%) and Incyte (5.6%).<ref name="AR 2024 "/>
== Company structure == The Chairman of the Board of Directors since 2024 is Thomas von Planta; the Vice Chairman is Clive A. Meanwell.<ref name ="board" />
Bellevue Asset Management AG, which belongs to the Swiss Bellevue Group and is based in Zurich,<ref>{{cite web |title=Bellevue Asset Management AG |url=https://zh.chregister.ch/cr-portal/auszug/auszug.xhtml?uid=CHE-107.402.972 |access-date=2025-09-02 |work=Handelsregister}}</ref> is commissioned with the areas of fundamental analysis, portfolio management, marketing and administration.<ref>{{cite web |title=Investmentstrategie |url=https://www.bbbiotech.ch/ch-de/private/portfolio-strategie/strategie/investmentstrategie |access-date=2022-03-28 |work=BB Biotech |language=de}}</ref> The investment management team has been headed Christian Koch since 2025.<ref>{{Cite web |last=Grundlehner |first=Werner |date=2025-01-24 |title=Bellevue-Chef: «Küsnacht ist schön, aber in der Stadt herrscht eine andere Dynamik» |url=https://www.tippinpoint.ch/artikel/77850/bellevue-chef_kuesnacht_ist_schoen_aber_in_der_stadt_herrscht_eine_andere_dynamik.html |access-date=2025-09-02 |website=Tippinpoint |language=de}}</ref>
BB Biotech's equity capital in the individual biotech companies is invested indirectly via the wholly owned subsidiaries Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., Biotech Growth N.V., all of which are seated in Curaçao.<ref name="HR_SH" />
== Company figures == Company figures are as follows:<ref>{{cite web |url=http://www.finanzen.net/bilanz_guv/BB_Biotech |title=BB Biotech |work=Finanzen.net |language =de |access-date=2024-07-01}}</ref><ref>{{Cite web|url=https://www.bbbiotech.ch/en/nc/bb-biotech/investor-relations/facts-figures/|title=BB Biotech – Facts & Figures |date=2020-03-11 |work=BB Biotech |url-status=live |archive-url=https://web.archive.org/web/20160321164301/http://www.bbbiotech.ch/en/nc/bb-biotech/investor-relations/facts-figures/ |archive-date=2016-03-21 |access-date=}}</ref>
{| class="wikitable" |- ! style="width:200px; background:#ccc;" | (figures in millions CHF) !2025 !2024 !2023 !2022 !2021 !2020 !2019 !2018 !2017 !2016 !2015 |- || Profit/(Loss) |578<ref name="AR 2025" /> |76<ref name="AR 2024">{{cite web |url=https://report.bbbiotech.ch/2024/en/download-center |title=Annual Report 2023 |work=BB Biotech |date=2025 |access-date=2025-04-01}}</ref> |(207)<ref name="AR 2023">{{cite web |url=https://report.bbbiotech.ch/2023/app/uploads/BION_GB2023_EN.pdf |title=Annual Report 2023 |work=BB Biotech |date=2024 |access-date =2024-06-29}}</ref> |(358)<ref>{{Cite web |title=Annual Report 2022 |url=https://report.bbbiotech.ch/2022/en/download-center/ |access-date=2023-08-31 |work=BB Biotech}}</ref> |(405) |691<ref name="ft_BION">{{cite web |title=BB Biotech AG, BION:SWX financials |url=https://markets.ft.com/data/investment-trust/tearsheet/financials?s=BION:SWX&subview=IncomeStatement |work=Financial Times Markets |access-date=2023-08-31}}</ref><ref name="F&F" /> |677 |(471) |688<ref>{{cite web |url=https://www.bbbiotech.ch/_Resources/Persistent/2/e/f/9/2ef97a1ab65f5477ce3c6166a91dc2d526963f38/BION_GB_2017_EN.pdf |title=Annual Report 2017 |work=BB Biotech |date=2018-02-16 |access-date=2024-07-01}}</ref> |(802) |653 |- || Net asset value |2,778<ref name="AR 2025" /> |2,286<ref name="AR 2024 "/> |2,323<ref name="AR 2023" /> |2,686 |3,283 |3,888<ref name="F&F" /> |3,393 |2,885 |3,539 |3,003 |3,978 |- || Market capitalization |2,490<ref name="AR 2025" /> |1,961<ref name="AR 2024 "/> |2,368<ref name="AR 2023" /> |3,058 |4,274 |4,108<ref>{{cite web |url=https://report.bbbiotech.ch/2020/en/ |title=Annual Report 2020 |work=BB Biotech |access-date=2021-10-20}}</ref><ref name="F&F">{{cite web |title=BB Biotech: Facts & Figures |url=https://www.bbbiotech.ch/en/bb-biotech/investor-relations/facts-figures |work=BB Biotech |access-date=2021-10-20}}</ref> |3,670 |3,235 |3,576 |3,053 |3,463 |}
==References== {{Reflist}}
==External links== *{{Official website|http://www.bbbiotech.ch}}
{{Authority control}}
Category:Investment companies of Switzerland Category:Investment management companies of Switzerland Category:Companies listed on the SIX Swiss Exchange Category:Companies listed on the Frankfurt Stock Exchange Category:Companies listed on the Borsa Italiana Category:Financial services companies established in 1993 Category:Swiss companies established in 1993 Category:Companies based in the canton of Schaffhausen Category:Schaffhausen